Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06106945 · ClinicalTrials.gov registry record · Phase 1
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 226
- Enrollment target
- 20
- Study locations
NCT06106945 is a Phase 1 study of Multiple Myeloma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 226 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06106945, a Phase 1 study of Multiple Myeloma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 226 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
Conditions Studied
Interventions
- DRUG AZD0305
Study Locations (20)
Other
- Research Site - Melbourne
- Research Site - Nedlands
- Research Site - Nova Scotia
- Research Site - Beijing
- Research Site - Changsha
- Research Site - Guangzhou
- Research Site - Shenyang
- Research Site - Lille
California
- Research Site - Duarte
- Research Site - Irvine
Ontario
- Research Site - Hamilton
- Research Site - Ottawa
Georgia
- Research Site - Atlanta
Massachusetts
- Research Site - Boston
Michigan
- Research Site - Ann Arbor
Missouri
- Research Site - St Louis
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2027-08-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06106945
The ClinicalTrials.gov registry entry for NCT06106945 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which AZD0305 is the first listed.
NCT06106945 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Ontario.
Frequently Asked Questions
What is clinical trial NCT06106945 about?
NCT06106945 is a clinical study titled "AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma". This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0305 in participants with RRMM.
What is the current status of trial NCT06106945?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 226 participants. The study started on 2023-12-05. Estimated completion is 2027-08-16.
What conditions does trial NCT06106945 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06106945?
The interventions under investigation include: AZD0305 (DRUG).
Who is sponsoring clinical trial NCT06106945?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06106945 being conducted?
This trial has 20 study locations across California, Georgia, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.